FeesSafety
Pluang+

CNB Financial reports Q3 2026 earnings of $0.91 per share, driven by loan growth and ESSA acquisition impact.

Company Fundamentals
21 Oct 2026, 23:05 WIB
GlobeNewsWire
View Source
Bullish
CNB Financial reports Q3 2026 earnings of $0.91 per share, driven by loan growth and ESSA acquisition impact.

CNB Financial Corporation announced Q3 2026 net income of $27.0 million, or $0.91 per diluted share, stable from Q2 and up from $18.9 million a year ago. The increase reflects organic loan growth and benefits from the ESSA Bancorp acquisition. Loans rose to $6.5 billion excluding syndicated loans, with growth in commercial and residential real estate loans. Deposits were $7.0 billion, slightly down due to strategic exit of higher-cost corporate deposits. The bank maintained a strong net interest margin of 3.89% and solid asset quality despite some charge-offs. CNB remains well-capitalized and optimistic about future loan and deposit growth.

CNB Financial Corporation's Q3 2026 results provide context for financial sector activity. For readers following Financials, here is Pluang's market snapshot as of Oct 22, 2026 03:02 WIB: Out of 142 priced Financials-sector US stocks tradable on Pluang, 106 rose and 36 fell today. Notable movers include WULF (TeraWulf Inc) at USD 12.88 with a 7.24% increase, PURR (Hyperliquid Strategies Inc Common Stock) at USD 9.65 up 5.46%, and BTBT (Bit Digital Inc) at USD 0.95 rising 5.18%. Typical hold times range from 4 to 19 days, with varying Pluang order activity percentages.

More News

Science 37 named BioSpace 2027 Best Place to Work for innovative clinical trial model and culture

Science 37 named BioSpace 2027 Best Place to Work for innovative clinical trial model and culture

Science 37, a direct-to-patient clinical research site, was named a BioSpace 2027 Best Place to Work, recognized for its innovative culture and commitment to clinical quality. The company’s model brings clinical trials to patients' homes, improving a...

Others
Bullish
1 hour ago
Peptide therapeutics market to hit $229B by 2036, driven by GLP-1, oncology, and generics growth

Peptide therapeutics market to hit $229B by 2036, driven by GLP-1, oncology, and generics growth

The global peptide therapeutics market is projected to grow from $112.2 billion in 2026 to $229.32 billion by 2036, at a CAGR of 7.4%. Growth is fueled by expanding use of GLP-1 and incretin therapies, advances in peptide engineering, new oncology ap...

Bullish
1 hour ago
New AI tool Book Leopard cuts Amazon book marketing costs to under $50 with fast, quality covers and ads.

New AI tool Book Leopard cuts Amazon book marketing costs to under $50 with fast, quality covers and ads.

Book Leopard, a new AI software, enables authors and publishers to create professional-quality Amazon book marketing materials in seconds for a one-time fee of $49, drastically reducing costs from over $1,000 and weeks of waiting. The tool generates ...

Others
Bullish
2 hours ago
Global nucleic acid labeling market to hit $2.8B by 2032, driven by genomics and diagnostics growth.

Global nucleic acid labeling market to hit $2.8B by 2032, driven by genomics and diagnostics growth.

The global nucleic acid labeling market, valued at $1.7 billion in 2025, is projected to grow to $2.8 billion by 2032 at a 7% CAGR. Growth is fueled by advances in genomics, molecular diagnostics, and personalized medicine, with increasing demand for...

Market News
Bullish
2 hours ago
MonetizeMore launches AI tool to help publishers avoid Google AdSense bans.

MonetizeMore launches AI tool to help publishers avoid Google AdSense bans.

MonetizeMore introduced the AdSense Policy Grader, an AI-powered tool that audits websites for compliance with Google's ad policies to prevent account bans and revenue loss. The tool offers a free basic report and a detailed paid report covering 79 p...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App